To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Cryoport shares rally following Blackstone’s bet on cell and gene therapy; Dyal’s latest GP stakes fund expected to surpass $5bn target; Levine Leichtman buys Bridgepoint Development’s BigHand
Blackstone invests in Cryoport causing the latter's stock to soar and Levine Leichtman acquires BigHand from Bridgepoint Development.
